Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan

Table 2 Outcomes for the 84 virologically suppressed HIV-infected patients entered in this study

	All	NVP-XR	NVP-IR	P
	N = 84	N = 35	N = 49	P
Ability to maintain a virological response, n (%)	71 (84.5)	29 (82.9)	42 (85.7)	0.72
Reason for treatment failure
Death, n (%)	0 (0.0)	0 (0.0)	0 (0.0)
Switch to other cART due to adverse effect or other cause, n (%)	4 (4.8)	2 (5.7) ^a	2 (4.1)	1.00
Virological failure, n (%)	2 (2.4)	1 (2.9)	1 (2.0)	1.00
Loss to follow-up, n (%)	6 (7.1)	3 (8.6)	4 (8.1)	1.00
Virological blip, n (%)	6 (7.1)	4 (11.4)	2 (4.1)	0.23
Change from baseline in CD4 T-cells, mean cells/mm³ (± SD)	14 (122)	23 (171)	76 (127)	0.33

cART combined antiretroviral therapy, NVP nevirapine, SD standard deviation
^aOne patient in the NVP-XR group discontinued NVP-XR because of insufficient supply of the drug

ISSN: 1471-2334